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PENILAIAN MASA UNTUK MENCAPAI BERAT BADAN  
KERING MENGGUNAKAN PEMANTAUAN KOMPOSISI 
 BADAN, PENGURUSANHIPERTENSI DAN PREVALEN 
 DALAM KALANGAN PESAKIT HEMODIALISIS  
DI KELANTAN MALAYSIA 
 
ABSTRAK 
 
 Hampir 60-90% pesakit hemodialisis (HD) mempunyai hipertensi. 
Pencapaian dan pengekalan berat kering merupakan strategi yang berkesan dalam 
mengawal dan mengekalkan normotensi dalam kalangan pesakit hipertensi yang 
menerima terapi HD. Pemonitoran komposisi badan (BCM) membantu dalam 
penganggaran status penghidratan pesakit dan berat kering dengan lebih tepat. Bagi 
tujuan ini, kajian ini menentukan masa pesakit mencapai berat kering selepas dialisis 
dengan menggunakan spektroskopi bioimpedan (BIS) di Hospital Universiti Sains 
Malaysia (HUSM), iaitu sebuah hospital penjagaan lestari beserta dengan sekumpulan 
pusat rawatan swasta di Kelantan, Malaysia. Dalam kajian prospektif, sejumlah 220 
pesakit HD dinilai tahap lebihan bendalir dengan menggunakan pemonitoran 
komposisi badan Fresenius (BCM). Pengukuran BCM diambil  sebanyak dua kali iaitu 
pada 30 dan 45 minit selepas pemeriksaan. Daripada jumlah 220 pesakit,120 (54.5%) 
mencapai keadaan euvolemik selepas 30 minit, manakala 25 orang (11.4%) selepas 45 
minit. Dalam analisis multivariat, akses vaskular selain fistula arteriovenous (AVF) 
(OR = 0.286, nilai p = 0.049) dan penyakit kardiovaskular (OR = 0.384, nilai p = 
0.026) mempunyai hubung kait negatif manakala penerimaan terapi hemodialisis di 
HUSM (OR = 2.705, nilai p = 0.008) mempunyai hubung kait positif yang juga 
signifikan pada keadaan euvolemik dicapai dalam masa 30 minit. Tambahan lagi, kami 
menilai kawalan hipertensi dan faktor-faktor yang mempengaruhi kawalan hipertensi 
 xiv 
 
dalam kalangan pesakit hemodialisis hipertensi euvolemik. Kajian ini mengambil kira 
data 145 pesakit hemodialisis euvolemik.  Pada lawatan asas, purata tekanan sistolik  
dan diastolik pra-dialisis peserta kajian adalah masing-masing 161.2 ± 24 dan 79.21 ± 
11.8 mmHg  manakala 30 (20.6%) pesakit berada pada tekanan darah pradialisis 
sasaran. Pada akhir pemeriksaan selepas enam bulan, purata tekanan darah pra-dialisis 
sistolik dan diastolik pesakit adalah 154.6 ± 18.3 dan 79.2 ± 11.8 mm Hg manakala 42 
(28.9%) berada pada tekanan darah pra-dialisis. Sasaran analisis multivariat, 
penggunaan ubat perencat saluran kalsium (CCB) adalah satu-satunya pemboleh ubah 
yang mempunyai persamaan statistik yang signifikan dengan hipertensi terkawal 
pradialisis pada awalan (OR = 7.530, p-value = 0.001) dan akhir (OR = 8.988, nilai 
<0.001) lawatan. Bagi enilaian prevalens dan peramal kemurungan dalam kalangan 
pesakit HD, kajian susulan prospektif dijalankan. Sejumlah 220 orang pesakit telah 
direkrut dalam kajian yang layak dan lengkap pada lawatan asas. Seterusnya, 216 dan 
213 pesakit masing-masing menyelesaikan soal selidik pada kedua dan akhir susulan. 
Prevalen kemurungan dalam kalangan pesakit di peringkat awal, pada kunjungan ke-
2 dan lawatan terakhir masing-masing adalah 71.3%, 78.2% dan 84.9%. Rawatan yang 
diberikan kepada pesakit di pusat-pusat HD di bawah badan NGO (OR = 0.347, p-
value = 0.039) mempunyai persamaan yang signifikan dengan prevalen kemurungan 
pada lawatan akhir. Sebagai kesimpulan, kajian ini menunjukkan bahawa penilaian 
status isipadu pada 45 minit selepas pemeriksaan semua pesakit atau ke atas individu 
yang mempunyai faktor risiko yang dikenal pasti tidak mengalami euvolemia pada 30 
minit akan memberikan penilaian yang agak tepat bagi kebanyakan pesakit. Hal ini 
dapat membantu mengelakkan berlakunya anggaran yang berlebihan tentang 
hipertensi, menggalakkan penggunaan ubat anti hipertensi, secara rasional 
mengurangkan kesan buruk dan meningkatkan kualiti hidup pesakit. Hubung kait  
 xv 
 
positif yang diperhatikan di antara CCB dan hipertensi terkawal menunjukkan bahawa 
CCB adalah ubat antihipertensi yang berkesan dalam mengawal hipertensi dalam 
kalangan pesakit euvolemik HD. Disamping itu, kemurungan adalah lazim dalam 
peserta kajian semasa. Perkaitan signifikan secara statistik dicerap antara kemurungan 
dan HD di pusat-pusat NGO membuktikan kepuasan pesakit dan pengurusan 
kemurungan yang lebih baik di pusat-pusat tersebut.  
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EVALUATION OF TIME TO ACHIEVE DRY WEIGHT USING BODY 
COMPOSITION MONITOR, HYPERTENSION MANAGEMENT 
 AND PREVALENCE OF DEPRESSION AMONG 
 HEMODIALYSIS PATIENTS IN KELANTAN 
 MALAYSIA 
 
ABSTRACT 
 Almost 60-90 % hemodialysis (HD) patients are hypertensive. Achieving and 
maintaining dry weight appears to be an effective strategy for controlling and 
maintaining normotension among hypertensive patients on HD therapy. Body 
composition monitor (BCM) helps estimate patient hydration status and dry weight 
accurately. For this purpose, the present study aimed to determine the time at which 
the majority of patients achieve postdialysis dry weight using bioimpedance 
spectroscopy (BIS) at Hospital Universiti Sains Malaysia (HUSM), a tertiary care 
hospital and a group of private centers outside the hospital in Kelantan, Malaysia. A 
total of 220 HD patients were prospectively assessed for fluid overload using the 
Fresenius body composition monitor (BCM). BCM readings were taken at 30 and 45 
minutes postdialysis. Among the 220 patients included in this study, 120 (54.5%) 
achieved a euvolemic state at 30 minutes, and 25 (11.4%) achieved it at 45 minutes 
according to the BCM. In the multivariate analysis, vascular access other than 
arteriovenous fistula (AVF) (OR=0.286, p value=0.049) and cardiovascular disease 
(OR=0.384, p value=0.026) had a statistically significant negative association and 
receiving hemodialysis therapy at HUSM (OR=2.705, p value=0.008) had a 
statistically significant positive association with achieving a euvolemic state at 30 
minutes. Moreover, we evaluated hypertension control and factors influencing 
hypertension control among euvolemic hypertensive hemodialysis patients. This study 
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included 145 euvolemic hemodialysis patients. On baseline visit, the mean pre-dialysis 
systolic and diastolic BP (mmHg) of study participants was 161.2 ± 24. and 79.21 ± 
11.8 respectively, and 30 (20.6%) patients were on pre-dialysis goal BP. At the end of 
the 6-months follow-up, the mean pre-dialysis systolic BP and diastolic BP (mmHg) 
of the patients was 154.6 ±18.3 and 79.2 ±11.8 respectively, and 42 (28.9%) were on 
pre-dialysis goal BP. In multivariate analysis, the use of calcium channel blockers 
(CCB) was the only variable which had statistically significant association with pre-
dialysis controlled hypertension at baseline (OR= 7.530, p-value= 0.001) and final 
(OR= 8.988, p-value <0.001) visits. For the assessment of prevalence and predictors 
of depression among HD patients, prospective follow-up study was conducted. A total 
of 220 patients were judged eligible and completed questionnaire at the baseline visit. 
Subsequently, 216 and 213 patients completed questionnaire on second and final 
follow up respectively. The prevalence of depression among patients at baseline, 2nd 
visit and final visit was 71.3%, 78.2% and 84.9% respectively. Treatment given to 
patients at NGO’s running HD centers (OR= 0.347, p-value= 0.039) had statistically 
significant association with prevalence of depression at final visit. In conclusion, this 
study suggests that assessing volume status at 45 minutes postdialysis will provide a 
relatively accurate assessment for the majority of patients, will help to prevent the 
overestimation of hypertension, encourage the rational use of antihypertensive drugs, 
reduce adverse effects and improve patient quality of life. The positive association 
observed between CCBs and controlled hypertension suggests that CCBs are effective 
antihypertensive drugs in the management of hypertension among euvolemic HD 
patients. Statistically significant association observed between depression and HD at 
NGO’s running centers signifies patients’ satisfaction and better depression 
management practices at these centers.  
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
The excessive mortality of hemodialysis (HD) patients due to cardiovascular events is 
related mostly to hypertension and cardiac damage (Hur et al., 2013). Various studies 
have shown that strict volume strategy is associated with decrease blood pressure (BP) 
without drugs, causes regression of left ventricular hypertrophy (LVH) and prolongs 
survival in hemodialysis patients (Bernard Charra & Chazot, 2003; Ozkahya et al., 
1998). In clinical practice, two procedures are usually carried out for fluid management 
in dialysis patients that is subjective clinical assessment and the probing of dry weight 
procedure (Canaud & Lertdumrongluk, 2012). The concept of “dry weight” which has 
a history of more than half a century now, is routinely used in current practice in 
virtually all HD centers worldwide. However, the best way to assess fluid status and 
dry weight is still an unsolved issue (Onofriescu et al., 2012). Dry weight in dialysis 
patients is a variable entity which implies a state of near euvolemia (Raza et al., 2018). 
Tracking the optimal dry weight among dialysis patients requires enough time and 
skills of physicians, nursing staff and adequate therapy. New noninvasive technologies 
such as bioimpedence spectroscopy (BIS) can assess fluid status in a more accurate 
way (Velasco et al., 2012). Currently there is an uncertainty in determining the optimal 
time for BP measurement and BP targets among HD patients (Onofriescu et al., 2014). 
Bioimpedence spectroscopy also has been used successfully to guide HD patients 
toward normohydration and better BP control (Machek, Jirka, Moissl, Chamney, & 
Wabel, 2009). 
 2 
 
Hypertension is very common, not an easy task to diagnose it properly and usually 
uncontrolled among HD patients. There have been always controversies regarding the 
diagnosis and treatment of hypertension in this specific population (Agarwal et al., 
2014). It is still challenging to treat hypertension due to various unsolved problems 
and procedures for the management of hypertension in patients on dialysis (Taniyama, 
2016).  High pre-dialysis and post-dialysis BP recordings demonstrate a U-shaped 
association with mortality among patients on dialysis (Zager et al., 1998). Instead of 
initiating or intensifying antihypertensive treatment, strict sodium and volume control 
is the best strategy for the management of hypertension among hemodialysis patients. 
Antihypertensive treatment is only recommended when patients already achieving 
normal volume status but still in hypertensive state, except diuretics all other major 
antihypertensive classes are considered effective in the treatment of hypertension in 
dialysis patients (Georgianos & Agarwal, 2016).  
 Initiation of dialysis therapy causes surprising changes in the life of dialysis patients 
which leads to physical and mental stress. This is a reason why dialysis patients 
develop neuropsychiatric complications (Teles et al., 2014). Among these 
complications, depression ranked first due to its high prevalence and as it is associated 
with poor quality of life of patients and increased mortality. The prevalence of 
depression is much higher in dialysis patients as compared to general population and 
patients with other chronic diseases (Jiang et al., 2001; Kessler et al., 2003). 
As volume overload is the major risk factor for hypertension, little is known about the 
optimal time of dry weight achievement and euvolemic state in hemodialysis patients 
while employing post-dialysis BCM sessions. Moreover, almost no contribution is 
made towards hypertension control and risk factors associated with hypertension 
control in euvolemic hypertensive hemodialysis patients. Despite the high prevalence 
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of depression, predictors of depression and its impact on the life of hemodialysis 
patients has remained a neglected area. Therefore, the current study aimed to determine 
the optimal time of post-dialysis dry weight achievement by using bioimpedence 
technology, hypertension control and factors associated with hypertension control and 
prevalence and predictors of depression among hemodialysis patients.   
1.2 Dry weight  
In hemodialysis patients, the dry weight is defined as “the lowest tolerated postdialysis 
weight achieved via gradual change in postdialysis weight at which there are minimal 
signs or symptoms of hypovolemia or hypervolemia” (Agarwal & Weir, 2010). After 
achieving dry weight, the extracellular volume becomes normal (Charra et al., 1996). 
Incorrect assessments of dry weight are very risky as it either leads to chronic 
hypervolemia or chronic hypovolemia. Fluid overload assessment is quite difficult. 
Fluid assessment may be conducted by using different ways in routine clinical settings 
such as on the basis of physical signs of edema, high blood pressure (BP) and 
cardiovascular (CV) complications. In this connection, physical signs of edema may 
provide with rough estimates of excessive extracellular volume. Moreover, it requires 
retention of several liters of water before the appearance and visibility of physical signs 
of edema (Devolder, Verleysen, Vijt, Vanholder, & Van Biesen, 2010; van Dijk et al., 
2013). In addition to the above referred methods, ultrasonic evaluation of diameter of 
the inferior vena cava is another technique employed for assessment of fluid status. 
However, there could be a possibility of inter-patient and inter-operator variability in 
this case. Apart from this, several other biomarkers techniques may also be used for 
assessment of changes in fluid status such as “brain natriuretic peptide (BNP)” and 
“N-terminal pro-brain natriuretic peptide (NT-pro BNP)”. However, both of these are 
usually induced by presence of CV disease and it has been reported that these may also 
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buildup in patients suffering from chronic kidney disease (CKD), making the 
execution of these methods unsuitable to assess the status of fluids (Yilmaz et al., 
2014). More recently, another technique viz. bio-impedance spectroscopy has 
demonstrated better results regarding successful and fruitful assessment of fluid status 
and in estimation of dry weight among HD patients (Earthman, Traughber, Dobratz, 
& Howell, 2007). 
The term “Dry weight” was first introduced by Thomson in 1967 (Thomson, 
Waterhouse, McDonald, & Friedman, 1967). In previously conducted research 
achieving dry weight in HD patients has been widely associated with better prognosis 
and improved survival rates (Agarwal, Alborzi, Satyan, & Light, 2009). On the other 
hand, the under- and overestimation of dry weight in HD patients have been associated 
with unwanted consequences of adverse events and cardiovascular morbidity and 
mortality (Agarwal, 2005; McIntyre et al., 2008; Shoji, Tsubakihara, Fujii, & Imai, 
2004). Therefore, establishing the ideal weight and maintaining the fluid balance in 
these patients has always remained a priority for nephrologists and an ongoing goal of 
clinical research. The previously published research has reported BCM as the most 
accurate, reliable and valid technique for assessing the HD patients’ status and 
deciding about achieving the dry weight. In a study, BCM was used for the purpose of 
guiding the HD patients towards normohydration. The findings of the study reported 
that BCM guided 2L fluid decrease in hyperhydrated patients led to no intradialytic 
symptoms and a significant systolic BP reduction of 25 mm Hg. Similarly, in the same 
study, BCM guided 1.3 L increase in patients of adverse events group resulted in a 
remarkable 73% reduction in intradialytic symptoms without affecting BP level 
(Moissl et al., 2013). Similar positive results regarding the accuracy and validity of 
BCM in assessing hydration status in HD and PD patients have been reported from 
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Belgium, Thailand and Italy (Chongthanakorn, Tiranathanagul, Susantitaphong, 
Praditpornsilpa, & Eiam-Ong, 2009; Crepaldi et al., 2009; Devolder et al., 2010). 
1.2.1 Benefits of probing dry weight  
Exploring dry weight has been strongly supported by observational investigations. A 
study reported that 35 out of 40 patients exhibited normotensive status after 
accomplishment of the dry weight (Charra et al., 1996). In another published report 
related to “control of left ventricular mass among HD patients”, Kayikcioglu et al. 
have described the visible advantages of non-pharmacological treatment over the 
pharmacologic treatment (Kayikcioglu et al., 2008). In this regard a case control study 
may be presented wherein results obtained from different patients treated at two 
different centers were compared. In this comparative study, non-pharmacological 
methods such as salt restriction and dry weight reduction were used for patient 
treatment at one center; while pharmacological method such as antihypertensive based 
therapy for managing of hypertension was employed at the other center. It was 
observed that the former center using “dry weight and salt restriction” (non-
pharmacological) as a top priority for patient treatment demonstrated better “diastolic 
and systolic left ventricular function”, lower usage of antihypertensive drugs, fewer 
episodes of intradialytic hypotension, lower interdialytic function and lower left 
ventricular mass. These observations provide useful clinical information and suggest 
that in-depth investigation of dry weight is a significantly useful strategy with better 
clinical outcomes in contrast to the antihypertensive based drugs strategy. Although 
the findings from a case control study may not always be conclusively precise, yet the 
results obtained from such a study do favor the advantages of ‘non-pharmacological’ 
against the ‘pharmacological therapy’ to effectively manage hypertension in patients 
with end stage renal disease (ESRD) (Kayikcioglu et al., 2008). 
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1.2.2 Assessment of dry weight  
In a study conducted by Agarwal and his co-authors, it was found that some of the 
procedures for dry weight assessment like diameter of ‘inferior vena cava’, volume of 
plasma & inflammation markers and monitoring of blood volume were not the 
essential determinants of edema (Agarwal, Andersen, & Pratt, 2008). Dry weight 
assessment and its achievement is considered to be an iterative process usually 
associated with some painful intradialytic symptoms like hypotension, dizziness, 
cramps etc. Due to these symptoms, various interventions are recommended including 
discontinuation of ultrafiltration, premature cessation of dialysis, patient’s head-down 
positioning or administration of saline. It has been reported that the practice of keeping 
a patient in head down position gives uncertain results and it may not essentially 
control BP of such patients (Bridges & Jarquin-Valdivia, 2005); however, it has been 
observed that ventricular filling pressure can be effectively raised by passively raising 
the legs of the patient without lowering the head (Jabot, Teboul, Richard, & Monnet, 
2009). The dry weight can be accomplished effectively by adequate ultrafiltration in 
dialysis sessions and by regular monitoring and comparison with previously recorded 
dry weight of the patients. Having mentioned all the above referred facts, it is still valid 
to state that a BCM employing the principle of bioimpedence technology can be used 
more successfully for obtaining the most accurate and precise patient’s dry weight 
estimation.  
1.3 Bioimpedence spectroscopy  
Bioimpedence spectroscopy is a uniquely modern method employed to assess 
distribution of fluid in either of the healthy and/or diseased population. BCM using 
bioimpedence technology provides a validated technique after its intensive validation 
using various gold standards in normal population or in HD patients (Devolder et al., 
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2010; Wabel, Chamney, Moissl, & Jirka, 2009). However, few investigations could 
come with successful validation with respect to non-dialysis-dependent chronic kidney 
disease (NDD-CKD) population.  
“BIS is a non-invasive trouble-free technique which can be used for the determination 
of body fluids amount and for body composition with respect to lean tissue and fat 
tissue mass”. This technique may be used for measuring the “total body water (TBW)” 
and also for separation between “extracellular & intracellular water (ECW & ICW)” 
(Earthman, Traughber, Dobratz, & Howell, 2007). ‘TBW’ represents the simple sum 
of ECW & ICW, where ECW is comprised of plasma water, interstitial water and the 
trans-cellular water, while the ICW consists of intra-cellular water with the cells being 
protected by cell membrane (Ferrario et al., 2014).  
The whole-body impedance spectroscopy method uses current with multi-frequency 
(5-1000 kHz) and low amplitude. In case of low frequency, the above referred current 
can only pass through extracellular water because of its inability to pass through the 
cell membranes while the current passes at high frequency through TBW (Hung et al., 
2015; Tsai et al., 2014). According to basic principle of BIS, when multi-frequency 
current is applied throughout the body, resistance is offered by every compartment of 
the body in response to applied current which is directly proportional to TBW and 
electrolytes of that compartment. Lean tissue is considered as an excellent conductor 
of electric current because of having water and electrolytes in large quantities with a 
little resistance to current flow. In contrast, bones & fats have smaller amount of water 
and electrolytes, so they offer high resistance to current flow (Mialich, Sicchieri, & 
Junior, 2014).  
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It has been reported that fluid overload (FO) value or over hydration (OH) can best be 
defined in terms of ECW and is generally expressed in liters (Ferrario et al., 2014). 
“Over hydration (OH) represents the extracellular water (ECW) content in those 
tissues which may be predicted by the help of physiological models under normal 
conditions. Thus, the values of OH obtained with the use of BCM can be compared 
with the values obtained from general population” (Hung et al., 2015).   
1.3.1 Clinical uses  
“Bioimpedence spectroscopy is a unique and modern tool generally required and used 
by health care skilled persons for determination of patient’s hydration status and for 
differentiation between ECW and ICW”. Nutritionist use this technique for various 
purposes in clinics as well as in weight management centers. This device is quite 
helpful in the management of hypertension and maintaining euvolemia according to 
patient needs as the device is perfect for appropriate assessment of total body water 
and BP. The most important use of BIS is in hemodialysis patients. By the help of BIS, 
we can determine urea distribution volume “V” in dialysis patients that is the volume 
of fluid which should be removed during the dialysis process (Mialich et al., 2014). 
1.3.2 Limitations  
For the last several years, relevant experts have extensively validated the BIS based 
body composition in healthy as well as in diseased population. Despite many 
advantages of the technique like easy handling, providing quick results and easy 
interpretations there are still some limitations associated with this technique. Due to 
difficulty in attachment of electrodes to the hands and feet of the patient, BIS may not 
conveniently have used in many cases including, but not limited to, patients with 
amputations or pacemakers, pregnant females and patient with various skin infections. 
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In some other conditions such as retention of water (Congestive cardiac failure and 
liver cirrhosis) and in cases of water-electrolyte imbalance, the results will not be that 
much accurate. Heavy meals, dehydration, menstrual cycle and intense physical 
exercise are among the other factors which can affect the accuracy of results (Charra, 
2007). 
1.4 Chronic kidney disease 
1.4.1 Background 
The heterogeneous group of disorders which affect the structure and functions of 
kidney are referred to as chronic kidney disease (CKD) (Levey et al., 2003). Keeping 
in view the increasingly large number of kidney failure cases and, more importantly, 
the alarmingly high number of patients suffering from kidney-cum-cardiovascular 
diseases which undoubtedly contribute in enhancing premature deaths even before 
reaching the condition of kidney failure, a global initiative to address such issues 
would not only be considered as rational rather ‘a must be done activity’ (Levey et al., 
2005). In this connection, many efforts have been made for improvement of the 
relevant outcomes and also for the betterment of CKD patients care in order to stop 
them reaching toward the sever condition of kidney failure. However, the desired 
objectives were not achieved, perceivably due to reasons including paucity of data 
obtained from clinical trials in the area of nephrology and also due to lack of any valid 
definition capable enough to agreeably categorize CKD patients in terms of severity. 
Therefore, it is being felt and does merit to properly define disease severity of CKD 
patients and to classify, in a candid manner, different levels of risk in order to ascertain 
suitable treatment of such patients and to help prevent continuation and/or 
advancement of the disease towards renal failure (Levin et al., 2010). 
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1.4.2 Definition 
“According to the National Kidney Foundations’ (NKF) clinical practice guidelines 
produced through the NKF Kidney Disease Outcomes Quality Initiative (NKF 
KDOQI), CKD is defined as kidney damage for ≥ 3months, as defined by structural or 
functional abnormalities of the kidney, with or without decrease glomerular filtration 
rate (GFR), manifest by either pathological abnormalities or marker of kidney damage, 
including abnormalities in composition of blood or urine or abnormalities in imaging 
test or “GFR < 60 ml/min/1.73m2 for ≥ 3 months, with or without kidney damage” 
(Levey et al., 2002).  
1.4.3 Classification / Staging of kidney disease 
NKF-KDOQI proposed the following five stages of CKD.  
Table 1.1 Classification of Chronic kidney disease 
CKD staging GFR(ml/min/1.73m2) 
1 ≥90 
2 60-89 
3 30-59 
4 15-29 
5 <15 
Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (Levey et al., 2002).  
Stage 1 shows the least complicated stage while the end stage renal disease with 
significant loss of renal function is depicted in stage 5.    
After its introduction in 2002, several suggestions have been considered to modify the 
kidney staging system.  In this connection, following three main modifications were 
proposed in International Controversy Conference 2009 (Levin et al., 2010): 
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1. The known cause of disease should be added to CKD staging as it plays a prime 
role in prediction of outcomes leading towards making decisions to select 
suitable treatment 
2. The “CKD stage 3 (GFR 30 – 59 ml/min/1.73m2)” should be divided into two 
sub-stages viz. 3a (45 < eGFR < 59) and 3b (30 < eGFR < 44)  
3. Albuminuria should also be added to CKD staging in order to assess disease 
severity 
Keeping in view the above referred recommendations, “the Kidney Disease Improving 
Global Outcomes (KDIGO) suggested a cause-GFR-albuminuria (CGA) 
categorization of CKD which is summarized as under”. 
Table 1.2 KDIGO classification of chronic kidney disease 
GFR category GFR(ml/min/1.73m2) Level of kidney function 
G1 ≥90 Normal or high 
G2 60-89 Mild decreased 
G3a 45-59 Mild to moderate decreased 
G3b 30-44 Moderate to severe decreased 
G4 15-29 Severe decreased 
G5 <15 Kidney failure 
Albuminuria 
category 
AER (mg/24 hour) Level 
A1 <30 Normal to mild increased 
A2 30-300 Moderate increased 
A3  >300 Severe increased 
GFR: glomerular filtration rate; AER: albumin excretion rate 
Improving global outcomes controversies conference (Levin et al., 2010).  
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1.5 End stage renal disease   
“It is a condition where GFR levels are less than 15 ml/min/1.73m2 and is also 
accompanied with signs and symptoms of uremia”. ESRD-patients require the therapy 
of renal replacement that may be performed by the process of dialysis or through 
transplant (Levey et al., 2002).  
The process of protein metabolism can produce creatinine as one of its bi-product. As 
and when kidneys do not work properly and clearance from kidneys is reduced, the 
normal levels of creatinine, urea and uric acid would be elevated (Cockcroft & Gault, 
1976). Depending on kidney function, patients of stage 4 may also need dialysis. 
Basically, dialysis acts like artificial kidneys eliminating waste products and excessive 
electrolytes from the blood. The two types of dialysis commonly in practice are: 
1. Hemodialysis  
2. Peritoneal dialysis  
In hemodialysis, blood filtration takes place through specific dialysis filters and 
solution. Before starting HD for any patient, it is necessary to first create a vascular 
access that may help in drawing the blood into the dialysis machine in order to filter it 
through the membrane filters, and the dialysis solution is pushed through a pump onto 
the alternate side of the membrane filter to aid the process by ion exchange action. In 
this fashion, based on concentration gradient, waste products are drawn to the dialysis 
solution. After this, the waste products accumulated in the machine are pumped out 
and the blood is pumped back into patient’s body. Completion of this procedure 
usually takes about 4 hours (Saran et al., 2017).  
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However, the procedure of peritoneal dialysis (PD) is different from that of the HD. In 
PD a catheter is inserted in peritoneal cavity (PC) of the patient instead of vascular 
access creation. The dialysis solution used for filling of the peritoneal cavity is the 
same as used in case of HD and the waste products it is removed periodically (Wiggins, 
Johnson, Craig, & Strippoli, 2007).  
1.6 Prevalence of end stage renal disease  
The highest prevalent countries with respect to ESRD include Taiwan, Japan, Mexico, 
US and Belgium. According to mortality data of 2007 and based on comparable 
treatment modalities, the risk of mortality in ESRD patients in USA are 15% higher 
than those in Europe and 33% higher when compared to patients in Japan (Masereeuw 
& Stamatialis, 2017).  
According to the report of ‘US Renal Data System’, not less than 660,000 patients in 
USA are treated for renal failure every year. About 468,000 out of total ESRD patients 
happen to be use dialysis therapy while more than 193,000 have to opt for kidney 
transplant. According to 2013 data report, about 117,000 Americans suffered from 
kidney failure cases, 57.3% being male and 42.69% female patients. A total of 44.3% 
patients belonged to age group of 45 – 64 years. The primary causes for ESRD 
remained diabetes (37.4 %) and hypertension (25.2%) (Saran et al., 2017).  
According to “global burden of disease report 2010”, in the list of death cases chronic 
kidney disease ranked 27th in 1990 and 18th in 2010. It is observed that worldwide > 2 
million ESRD patients receive dialysis or kidney transplant (Couser, Remuzzi, 
Mendis, & Tonelli, 2011). In countries with middle income, ESRD treatment remains 
a financial burden over the needy patients. Many of them cannot afford it financially 
and consequently > a million patients die every year because of non-treatment of the 
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kidney failure complication. Worldwide, the estimated share of Europe is 13% in 
connection to prevalence of ESRD. Portugal, Germany Cyprus, Spain and Italy are 
among the countries with highest prevalence. In Europe, among 552,000 patients, 575 
are on HD, 5% with PD and 39% are alive after kidney transplant. Data show that in 
Europe kidney transplant is growing at faster rates with an average of 3% increase/year 
(Couser et al., 2011). According to a published report, in England the CKD associated 
cost is higher than the combined cost of lung, colon, skin and breast cancer, where the 
CKD related cost is estimated to become as high as $ 12 billion by 2020. Similarly, in 
Uruguay, annual cost of HD therapy is reportedly $ 23 million that is equal to almost 
30% of total budget allocated for all the specialized therapies. Finally, China has 
decided to spend about $558 billion on heart diseases and kidney failure cases over 
next decade (Nasri, 2014). 
1.7 Prevalence of end stage renal disease in Malaysia  
In Malaysia, the prevalence report of CKD demonstrated to be 4.16, 2.05, 2.26 and 
0.24% for stage 1, 2, 3 and 4, respectively while ESRD prevalence was reported as 
0.36% (Hooi et al., 2013). According to the 23rd report of the Malaysian dialysis and 
transplant registry (MDTR, 2015), a linear increase prevailed in the number of HD 
patients over 10 years where in 2006 the reported dialysis cases were 3710 which have 
been increased to 6479 cases in 2015. It has been reported that in Malaysia the rate of 
kidney transplant cases decreased to about 50% over last decade, probably due to easy 
and convenient availability of dialysis therapy; and it was estimated to be about 3 per 
million population (pmp) in the latest MDTR report (MDTR, 2015). According to this 
published report, there were 1118 new peritoneal dialysis cases with acceptance rate 
of 37 pmp. In 2015, the total number of HD and PD patients reached to 33,456 and 
3727, respectively that exhibit the respective prevalence rate of 1097 and 122 pmp. 
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Moreover, by year 2015, the rate of treatment of dialysis patients surpassed 
200/million population throughout Malaysian states except for Perlis and Sabah 
(MDTR, 2015).  
1.8 Complications associated with end stage renal disease  
Healthy kidneys have various important functions including removal of waste 
products, regulate hypertension, maintenance of electrolyte imbalances, maintain body 
fluids, production of calcitriol and production of urine. Moreover, Kidneys also 
produce erythropoietin which is responsible for red blood cells formation. When 
kidneys become impaired the equilibrium is disturbed which is maintained by normal 
kidneys resulting in variety of disorders. Common complications associated with 
ESRD are described as under: 
1.8.1 Cardiovascular disease as a complication of end stage renal disease  
The most frequent complication associated with ESRD is cardiovascular disease. It is 
reported that annual mortality rate is 44% associated with ESRD (Herzog, Ma, & 
Collins, 1998). Higher mortality rates are reported in HD patients as compared to the 
general population with respect to cardiovascular events despite stratification for 
gender, ethnicity or even age group. The incidence of cardiovascular mortality is 500 
times more in young dialysis patients as compared to cardiovascular patients in general 
population (Foley, Parfrey, & Sarnak, 1998).  Using the US renal database system, 
Herzog et al. studied 34,189 HD patients and found that poor prognosis prevailed 
among such patients who were suffering from acute infarction. Their published results 
showed that cardiovascular mortality rates were 51.8 and 70.2 % after 2 and 5 years, 
respectively (Herzog et al., 1998).  
 16 
 
It merits a mention that prevalence of cardiovascular events happened to constantly 
increase not only with the ESRD but also among the patients suffering from chronic 
kidney diseases. As glomerular filtration declines, elevation in prevalence of LVH 
would be observed and it is reported that clinical evidences related to ischemic heart 
disease were found in almost 30% of patients reaching ESRD.  Moreover, it is 
noteworthy that patients having more risk to die due to cardiovascular events with 
reduced glomerular filtration as compared to progression towards ESRD (Shulman et 
al., 1989).   
The relationship found between cardiovascular events and ESRD revealed to include 
common pathological links which further depend upon the prevalence of traditional 
and nontraditional reasons; where such traditional factors could be anemia, 
hypertension, dyslipidemia, electrolytes imbalances and acid-base or mineral related 
complications, whereas inflammation problems, oxidative stress and fluid overload 
may be included among the non-conventional factors (Shlipak et al., 2001). CKD-
Mineral and Bone Disorder (CKD-MBD) leads to increase in parathyroid hormone 
which actually increases the risk of cardiac mortality and also contributes to develop 
left ventricular hypertrophy like phenomenon, mainly due to presence of parathyroid 
receptors in the heart (Bhuriya, Li, Chen, McCullough, & Bakris, 2009). Additionally, 
parathyroid hormone can also cause atherosclerosis and increased vascular tone that 
may further lead towards hypertension, an important risk factor for cardiovascular 
diseases. Pro-inflammatory cytokines also releases due to malnutrition that may 
aggravate the existing inflammation and may also accelerate arthrosclerosis (Pecoits‐
Filho, Lindholm, & Stenvinkel, 2002).  Fluid overload, too, is a main cause of 
hypertension in ESRD patients which influences vascular functions and may lead 
towards left ventricular hypertrophy, atherosclerosis and/or arterial stiffness. 
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Interestingly, “Reverse causation,” wherein the CKD is considered as a risk factor 
complication such as CVD and vice versa, is another interpretation for possible 
association between the two diseases (Elsayed et al., 2007). Such an association 
existing between CKD and CVD is known as “cardio-renal syndrome” which may be 
defined as “the disorder of kidney or heart in which certain acute and/or chronic 
disorder present in one organ may induce an acute or chronic disorder into the other 
organ” (House et al., 2010).  
1.8.2 Hypertension as complication of end stage renal disease  
Usually, the ESRD patients suffer from hypertension, and its prevalence is up to 90% 
in such patients. As the kidney function declines, the prevalence of CKD related 
hypertension increases linearly. Among the HD patient’s pathogenesis of hypertension 
is very complicated and has not been perfectly explored yet. However, based on the 
known published research work it may be stated that, inter alia, hypervolemic 
conditions, renin angiotensin receptor blockers, enhanced sympathetic activity and 
altered endothelial cell functions could be the possible contributors out of so many 
relevant expected reasons (Ekart, Bevc, & Hojs, 2011) 
1.8.2(a) Volume overload induced hypertension 
Hemodialysis procedure replaced the excretory function of kidneys in hemodialysis 
patients. Absorption of salt and water is same between normal people and 
hemodialysis patients however their excretion requires hemodialysis procedure. In 
between each dialysis session, 1-3 liters of extracellular water is gained. These 
constant fluctuations lead to high blood pressure in hemodialysis patients (Doulton & 
MacGregor, 2004). Fluid intake is quantitative dependent on thirst of an individual 
which is turn is dependent on osmolality (Tomson, 2001) and that sodium 
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concentration may determine the osmolality. It may be said that Plasma osmolality 
dependent upon the intake of dietary salt and on the net amount of sodium gained or 
lost during the process of dialysis.  Excretion of sodium from kidney usually takes 
place within an hour (He, Markandu, & MacGregor, 2001). Almost similar mechanism 
is encountered in cases of kidney failure patient’s however such patients are unable to 
excrete sodium due to diseased kidneys, retention of sodium in plasma for longer than 
normal time occurs which causes   induction of thirst in such individuals.  Induction 
of thirst causes a higher intake of water and/or other fluids that culminate in 
overloading the volume which in turn results in higher BP observed among HD 
patients (Singer et al., 1998). Conclusively, reducing intake of salt is absolutely 
essential in on order to reduce thirst as well as interdialytic weight gains.  
Volume overload is the result of higher intake of fluid and retention of sodium in the 
body and this in turn affects the vascular system by non-hemodynamic influences. HD 
patients are at greater risk of cardiac failure when they begin dialysis with low pre-
dialysis blood pressure, this may lead towards poor prognosis of HD patients due to 
slower removal of fluid. On further aggregation and analysis of this scenario, it may 
be said that HD patients usually face diastolic dysfunction. In such HD patients, a little 
reduction in filling pressure after the dialysis procedure may cause reduced cardiac 
output followed by hypotension (Ekart et al., 2011).  
1.8.2(b) Renin angiotensin aldosterone system (RAAS) induced hypertension 
Blood pressure is regulated by a signaling pathway called renin-angiotensin-
aldosterone system (RAAS). Upon stimulation by hypotension or in certain cases like 
stressful situations kidneys tends to release an enzyme known as renin, which is 
responsible for generation of signal transduction pathway. The renin causes protein 
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angiotensinogen to convert into angiotensin-I that is further changed by “angiotensin 
converting enzyme (ACE into ‘angiotensin-II”) (Boulware et al., 2006).    
‘Angiotensin-II’ plays its role in vasoconstriction and simultaneous vasopressin 
secretion in the pituitary gland. Moreover, it also helps in release of adrenaline, nor-
adrenaline and aldosterone. ‘Adrenaline and nor-adrenaline’ increase 
‘vasoconstriction’ while ‘aldosterone’ may increase the renal filtration activity. 
Normal kidneys can usually contain more water & sodium and are capable to excrete 
higher levels of potassium. The water-retaining hormone viz. Vasopressin can prevent 
the excretion of water without having any significant effect on levels of sodium and 
potassium. In this process, the total blood volume in the body increases, consequently 
the constricted arteries would pump more blood that may create higher than normal 
pressure to be exerted on the artery walls resulting into higher blood pressure (Fig. 
1.1). 
 
Fig. 1.1 Renin angiotensin aldosterone system pathway (Britannica, 2017) 
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1.8.2(c) Increased sympathetic activity associated hypertension  
Hypertension caused by sympathetic activity is common among ESRD patients. 
Various studies reported increased sympathetic activity among HD patients (Converse 
Jr et al., 1992). Moreover, HD patients with bilateral nephrectomy have normal 
sympathetic activity, which leads towards the sympathetic activity hypothesis which 
relates to neurogenic signal of the renal afferents arising in the failing kidney 
(Augustyniak, Tuncel, Zhang, Toto, & Victor, 2002). 
It was reported in a study that sympathetic over activity can be normalized by the use 
of ACE inhibitors and not by calcium channel blockers in patients that are with renin 
dependent hypertension or with chronic renal insufficiency associated with 
Angiotensin-II related neural action, asymmetric di-methyl-arginine (ADMA) 
elevated levels, oxidative stress, nocturnal hypoxia, chronic inflammation and obesity 
are among the factors that contribute towards increased sympathetic activity (Levin et 
al., 2010).  
1.8.2(d) Parathyroid hormone associated hypertension  
Excessive secretion of parathyroid hormone results in inducing of intracellular calcium 
levels that are believed to be associated with hypertension among ESRD patients. The 
mechanism accountable for hypertension is based on the fact that vasoconstriction is 
caused by the calcium available in smooth muscles cells of blood vessels. It is 
noteworthy that administration of vitamin D or performing parathyroidectomy in 
patient on dialysis can result in reduction of BP (Raine et al., 1993).  
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1.8.2(e) Reduced production of prostaglandins/ bradykinins associated 
hypertension  
Normally, kidneys produce various vasodilating chemicals such as prostaglandins, 
kinins and antihypertensive neural reno medullary lipids. It has been observed that ups 
and downs in generation of these chemicals usually leads to hypertension in patients 
on hemodialysis. It has also been found that levels of prostaglandin (PgE2) production 
are lower in hypertensive HD patients. Moreover, in uremic patients usually a negative 
correlation exists between BP and prostacyclin metabolite 6-keto-PgF1α (Ekart et al., 
2011). 
1.8.3 Anemia as a complication of end stage renal disease  
Anemia is commonly observed problem with very high prevalence in both early as 
well as late stages of CKD. Roughly, all of the HD patients suffer from anemia. 
Anemia is also considered as a risk factor for CV complication, deteriorating life 
quality that may lead towards cognitive impairment and finally into mortality of the 
CKD patients (McCullough & Lepor, 2005). The basic mechanism of anemia in ESRD 
may be summarized as under (Babitt & Lin, 2012): 
• Erythropoietin (EPO) decreased production 
• Hepcidin, a liver hormone, controls availability of iron and can regulate both 
absorption of dietary iron as well as recycling of iron from RBCs. In chronic 
kidney disease, the decreased renal clearance and inflammation leads towards 
enhanced hepcidin levels that in turn causes the phenomenon of “iron restricted 
erythropoiesis”.  
• Erythropoietin related bone marrow’s unresponsiveness   
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1.8.4 Mineral and bone disorder complications  
“Systemic disorder of mineral and bone metabolism leads to a clinical syndrome called 
chronic kidney disease associated mineral and bone disorder (CKD-MBD) which is 
specifically due to CKD”. The following mechanisms have been proposed for CKD-
MBD (Komaba & Fukagawa, 2009): 
• Abnormal concentrations of parathyroid hormone, phosphate and calcium in 
serum.  
• Disturbances in Vitamin D metabolism. 
• Renal Osteodystrophy  
• Elevated levels of a hormone viz. fibroblast growth factor (FGF23) which is 
concerned with the process of metabolism with respect to minerals and 
Vitamin-D. 
• Vascular and soft tissue calcification.  
1.8.5 Uremic complication 
“Uremic syndrome refers to a series of complications which contribute towards the 
development and progression of CKD to ESRD”. These may include electrolyte 
disorder, retention of water, hormonal deficiency or resistances, compensatory 
response to body and last but not the least is retention of waste (Chikotas, Gunderman, 
& Oman, 2006). These uremic problems are considered to be due to reduction in eGFR 
and possible damaging action against the excretory and endocrine systems of the body. 
The common signs and symptoms of uremic complications include loss of appetite, 
pruritus, elevated level of blood urea and creatinine and neurological changes (Meyer 
& Hostetter, 2007).  
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1.8.6 Malnutrition-inflammation complication  
It is reported that in early stages of CKD there could arise protein-energy malnutrition 
which becomes prominent with significant decline in eGFR. The malnutrition-
inflammation complex syndrome (MICS) is basically collection of malnutrition and 
inflammation which generally coexist in CKD (Kalantar‐Zadeh, 2005). Inadequate 
diet results in abnormalities with several clinically markers such as “low albumin and 
transthyretin, lipids and elevated levels of C-reactive protein (CRP)”. Etiology of 
protein associated malnutrition in renal impaired patients is not clearly understood. 
The proposed mechanisms of protein malnutrition in renal impaired patients include 
resistances to insulin and growth hormone, metabolic acidosis, co-morbid conditions 
such as infections, aging and cardiovascular disorders (CVD), inadequate dietary 
intake, oxidative stress and endocrine disorder such as hyperparathyroidism. Lastly, 
inflammation is believed to be concerned with increased protein catabolism and with 
pro-inflammatory cytokines release that lead to loss of protein stores (Kalantar‐Zadeh, 
2005).  
1.9 Management of hypertension among hemodialysis patients 
In hemodialysis patients, management of hypertension is a complex procedure that 
requires in depth information about the pharmacokinetic as well as pharmacodynamic 
properties of the drugs used by such patients. It is considered that modification in life 
style can enormously affect management of hypertension in HD patients. Moreover, 
proper strategy of salt restriction is also important rather essentially required. In 
addition to all these, reduction of extracellular fluid and dry weight achievement are 
also considered to be among the most important factors in managing hypertension in 
HD patients and these should never be neglected (Fig. 1.2). 
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Fig. 1.2 Management of hypertension among hemodialysis patients [Source: 
KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patient (K/DOQI, 
2005)]. 
 
If lifestyle modifications are not that much successful in controlling hypertension, 
antihypertensive therapy is recommended. NKF KDOQI guidelines recommended that 
first line antihypertensive agents are ACE inhibitors or ARBs. In HD patients, ARBs 
can significantly reduce the left ventricular hypertrophy (LVH) and in this connection, 
they are found to be more effective as compared to ACE inhibitors (Cannella et al., 
1997; Guerin et al., 2001; Shibasaki et al., 2002). It has been recommended that in 
order to achieve control, alpha anti-adrenergic drugs and calcium channel blockers 
